In NCT03066648, TIM-3 monoclonal antibody MBG 453 is being explored for its safety and tolerability as a monotherapy or in combination therapy among patients with AML and intermediate or high-risk myelodysplastic syndromes (MDS). The gene discussed is HAVCR2; the disease is myelodysplastic syndrome.